AVACTA GROUP PLC Logo

AVACTA GROUP PLC

AVCT | IL

Overview

Corporate Details

ISIN(s):
GB00BYYW9G87
LEI:
2138009U3EG31OPMGH36
Country:
United Kingdom
Address:
UNIT 20 ASH WAY, THORP ARCH ESTATE, LS23 7FA WETHERBY
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Avacta Group PLC is a clinical-stage life sciences company focused on developing innovative cancer therapies through its proprietary pre|CISION® platform. This peptide drug conjugate (PDC) technology is designed to deliver anti-tumor payloads directly to the tumor, aiming to improve the safety and efficacy of potent cancer drugs and expand their therapeutic use. The company's pipeline includes targeted oncology drugs, with a key focus on advancing its assets through clinical trials and strategic partnerships. While historically involved in diagnostics, Avacta is increasingly concentrating its resources on its core therapeutics division.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for AVACTA GROUP PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-30 08:00
Earnings Release
Avacta to Present at ESMO Congress
English 17.3 KB
2025-07-28 08:48
M&A Activity
Agreement to Sell Coris Bioconcept SRL
English 17.8 KB
2025-07-21 08:00
Capital/Financing Update
Payment of Convertible Bond Installment
English 16.0 KB
2025-07-17 08:00
Share Issue/Capital Change
Equity fundraise of £3.25 million
English 42.4 KB
2025-07-02 18:00
Declaration of Voting Results & Voting Rights Announcements
Result of AGM
English 29.4 KB
2025-07-02 08:00
Regulatory News Service
Q2 2025 Business Update
English 25.6 KB
2025-06-06 08:00
Earnings Release
Preliminary Full Year 2024 Results
English 512.2 KB
2025-05-28 08:00
Board/Management Information
Board appointments
English 30.9 KB
2025-05-27 08:00
Report Publication Announcement
Update on timing of preliminary results
English 16.4 KB
2025-05-15 08:00
Report Publication Announcement
Notice of Results
English 15.4 KB
2025-05-08 08:30
Share Issue/Capital Change
Block Listing Application to AIM
English 13.2 KB
2025-04-28 18:52
Share Issue/Capital Change
Block Listing Six Monthly Return
English 25.8 KB
2025-03-31 08:00
Business and Financial Review
Avacta Quarterly Update
English 24.0 KB
2025-03-26 08:00
Regulatory News Service
Avacta Announces Presentations at AACR
English 18.7 KB
2025-03-25 08:00
M&A Activity
Avacta Completes Launch Diagnostics Sale
English 14.8 KB

Automate Your Workflow. Get a real-time feed of all AVACTA GROUP PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for AVACTA GROUP PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN